from TORONTO STAR
(Real estate agent) Krista Tabacoff Stryland, (1974-2007) was pronounced dead in North York Hosp shortly after paramedics took her there from GP Behnaz Yazdanfar’s cosmetic clinic (in a North Toronto office building).
The GP who was found incompetent in her care of cosmetic surgery patients – including Ms STRYLAND who died following a SIX LITER liposuction in 2007 .
Dr. Behnaz Yazdanfar was found to have displayed “disgraceful, dishonourable or unprofessional” conduct in her care of five patients following a TWO YEAR disciplinary hearing before the Ontario College of Physicians and Surgeons that ended in May 2011. PENALTY delayed for SEVEN MONTHS..
Yesterday the college suspended Yazdanfar’s licence for two years. After that, Dr. Yazdanfar will be restricted from SOLO surgery but will be permitted to ASSIST in surgery, including cosmetic procedures.
She was ordered Wednesday to appear before the college for a public reprimand within the next three months.
Yazdanfar was ordered to pay $219,000 in costs to the college within a year.
She must also co-operate with unannounced inspections of her practice and patient charts, conducted at her expense, and publish the terms of her restrictions at her clinic and on her website.
Like many doctors performing cosmetic procedures (in Ontario), Dr. Yazdanfar was never accredited as a plastic surgeon and holds no surgical designation.
Ms. Krista Stryland was pronounced dead in hospital shortly after paramedics took her from Dr.Yazdanfar’s cosmetic clinic. Court records obtained by the Star alleged Ms. Stryland lay in the clinic’s recovery room in serious condition for 30 minutes before anyone called 911.
Dr. Bruce Liberman, the anesthesiologist in the Stryland case, was also found to be incompetent. He is awaiting the result of a separate disciplinary hearing.
COMMENTS:
The CPSO was aware that GPs were perfoming surgery under GENERAL ANAESTHESIA in office buildings. The CPSO Registrar, past ER physician & CPSO Past President, , R.V. GERACE MD (UWO 72) FRCSC (ER 83) was aware of the danger for years and took no preventive action. As a direct result of this negligence a patient died; will Dr.Gerace resign?
Dr.Yazdanfar was represented by Lawyers Clayton Ruby CM BA(York 63) LLB (Tor.69) LLM(U.Cal.Berkeley) 11 Prince Arthur Av.,Yorkville,Tor. & Gardiner Roberts LLP partner Tracey Tremayne-Lloyd LLB( 83) Certificate in Health Law, They did a superb job: Dr. Yazdanfar did NOT lose her licence. Only a nominal "Suspension" for 2 years: no problem as the clinic can function withoout her medical services employing other doctors. Also Dr.Yazdanfar can do admin. duties. As for the CPSO legal costs of $219,000 (NOT A FINE) , this a moderate amount considering the gravity of the case. Also is TAX DEDUCTABLE.
World-wide medical news for clinical use. Contributions edited by Dr.A.Franklin MBBS(Lond)Dip.Phys.Med (UK) DPH & DIH(Tor.)LMC(C) FLEx(USA) Fellow Med.Soc.London
22 December 2011
KOREAN-CANADIAN VENTURE for AIDS VACCINE
Sumagen Canada Inc. is a solely owned subsidiary of Sumagen Co., Ltd.
Sumagen Co., Ltd is a Korean pharmaceutical venture company focusing on developing an HIV/AIDS vaccine and is a solely owned subsidiary of Curocom Co., Ltd. Sumagen is also supporting the ongoing research work at the Schulich School of Medicine and Dentistry, The University of Western Ontario (UWO) for and HCV (Hepatitis C Viru) vaccine.
Dr. Chil Yong Kang, Sumagen's Chief Scientific Officer and also a professor at UWO, developed a vaccine for HIV/AIDS for both therapeutic and prophylactic use with his team. In 2006, the company opened an office in London at the Stiller Centre, in order to closely support the vaccine development. The office in London with a staff of six, are managing the project to manufacture the materials for clinical trials, conduct non-clinical studies, and coordinate through a consultant to meet the requirements of the FDA in the United States to obtain approval to conduct human clinical trials.
Sumagen Co., Ltd is a Korean pharmaceutical venture company focusing on developing an HIV/AIDS vaccine and is a solely owned subsidiary of Curocom Co., Ltd. Sumagen is also supporting the ongoing research work at the Schulich School of Medicine and Dentistry, The University of Western Ontario (UWO) for and HCV (Hepatitis C Viru) vaccine.
Dr. Chil Yong Kang, Sumagen's Chief Scientific Officer and also a professor at UWO, developed a vaccine for HIV/AIDS for both therapeutic and prophylactic use with his team. In 2006, the company opened an office in London at the Stiller Centre, in order to closely support the vaccine development. The office in London with a staff of six, are managing the project to manufacture the materials for clinical trials, conduct non-clinical studies, and coordinate through a consultant to meet the requirements of the FDA in the United States to obtain approval to conduct human clinical trials.
Subscribe to:
Posts (Atom)